secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026100
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer
--------------------------------------------------------------------------------

- Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).
- Three of seven CAN-2409-treated patients still alive at data cut-off (66.0, 63.6, 35.8 months post-enrollment).
- Median survival post-progression was 21.2 months with CAN-2409 vs 7.2 months in control arm.
- No dose-limiting toxicities or pancreatitis; favorable safety profile.
- Company plans to advance CAN-2409 into a larger late-stage randomized trial in PDAC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/0000950170-25-026100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/cadl-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer